Literature DB >> 7993955

Is platelet imipramine binding reduced in depression? A meta-analysis.

P M Ellis1, C Salmond.   

Abstract

Although it has been suggested that decreased platelet imipramine binding may be a putative biological marker of depressive illness, a number of studies have not confirmed this finding, including a recent multicenter investigation by the World Health Organization (Mellerup and Langer 1990). We performed a meta-analysis of published reports on imipramine binding in groups of depressed and healthy control subjects and found that there was a highly significant decrease in Bmax (maximal binding) values in the depressed subject groups, which was even greater among those who had been free of medication for 4 weeks at the time of investigation. This finding remained highly significant even when only high affinity binding studies (Kd < 1 nmol/L) were considered, although the absolute size of this decrease was smaller.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7993955     DOI: 10.1016/0006-3223(94)90626-2

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  16 in total

1.  Cocaine and antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A.

Authors:  A L Bauman; S Apparsundaram; S Ramamoorthy; B E Wadzinski; R A Vaughan; R D Blakely
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

Review 2.  Pathophysiological basis of cardiovascular disease and depression: a chicken-and-egg dilemma.

Authors:  Gilberto Paz-Filho; Julio Licinio; Ma-Li Wong
Journal:  Braz J Psychiatry       Date:  2010-06       Impact factor: 2.697

Review 3.  The role of neurotransporters in excitotoxicity, neuronal cell death, and other neurodegenerative processes.

Authors:  K P Lesch; A Heils; P Riederer
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

4.  Serotonin transport kinetics correlated between human platelets and brain synaptosomes.

Authors:  Jeffrey L Rausch; Maria E Johnson; Junqing Li; Julian Hutcheson; Benjamin M Carr; Katina M Corley; Amanda B Gowans; Joseph Smith
Journal:  Psychopharmacology (Berl)       Date:  2005-02-22       Impact factor: 4.530

5.  The human serotonin transporter gene polymorphism--basic research and clinical implications.

Authors:  A Heils; R Mössner; K P Lesch
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

6.  Binding of paroxetine to the serotonin transporter in membranes from different cells, subcellular fractions and species.

Authors:  A Cupello; C Albano; E Gatta; S Scarrone; E Villa; G Zona
Journal:  Neurochem Res       Date:  2008-06-18       Impact factor: 3.996

7.  Evolving refractory major depressive disorder diagnostic and treatment paradigms: toward closed-loop therapeutics.

Authors:  Matthew P Ward; Pedro P Irazoqui
Journal:  Front Neuroeng       Date:  2010-05-31

8.  Active platelet 5-ht uptake in depressives treated with impramine and ect.

Authors:  P K Dalal; N Lal; J K Trivedi; P K Seth; A K Agarwal; A Khalid
Journal:  Indian J Psychiatry       Date:  1998-01       Impact factor: 1.759

Review 9.  The genetic relationship of personality to major depression and schizophrenia.

Authors:  Ayman H Fanous; Kenneth S Kendler
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

10.  Acute tryptophan depletion evokes negative mood in healthy females who have previously experienced concurrent negative mood and tryptophan depletion.

Authors:  Oliver J Robinson; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2009-04-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.